Early and accurate detection of respiratory viruses is critical to improving patient outcomes and preventing the spread of disease. It is known that:
The Centers for Disease Control (CDC) states that viral infections are a major cause of hospitalizations in young children and the elderly, and represent the seventh leading cause of death in the United States,1 with annual direct and indirect costs estimated at more than US $10 billion per year.2 From influenza alone, each year, over 200,000 Americans are hospitalized and 36,000 of them die from their infection.1 A New England Journal of Medicine study of children with influenza showed that only 28% of hospitalized and 17% of outpatient children were accurately diagnosed by their physician, echoing the need for rapid influenza testing.3
Detect multiple respiratory viruses, the majority of which readily circulate among the most vulnerable populations—children, the elderly, and the immunocompromised—with xTAG® Respiratory Viral Panel (RVP).
Tests for 19 different respiratory viruses including Flu A subtypes (H1, H3 and H1N1 (2009)) in a single assay
Excellent clinical sensitivity and specificity
The xTAG RVP FAST v2 assay is a qualitative nucleic acid multiplex test intended for the simultaneous detection and identification of multiple respiratory virus nucleic acids from nasopharyngeal swabs from individuals suspected of respiratory tract infections. This robust assay uses the proprietary Luminex xTAG Technology and xMAP® Technology platform to detect multiple targets in a single sample, enabling more accurate and efficient patient diagnosis.
The xTAG RVP FAST v2 assay includes two controls (MS-2 and Lambda DNA) to ensure assay performance.
The following table shows clinical targets detected by each respiratory viral panel based on regional regulatory clearances.
|Viral Subtypes||CE Marked in EU and
|Respiratory Syncytial Virus (RSV)||•|
|Influenza A matrix||•|
|Entero-Rhinovirus (Reported as Rhinovirus only in US.)||•|
|xTAG MS-2 Bacteriophage Internal Control|
|xTAG bacteriophage Lambda DNA Control|
xTAG Respiratory Viral Panel (RVP) – Clinician Brochure
Better Know Your xTAG RVP Buffers! – Luminex Blog
Note: Luminex manufactures and distributes products mentioned in the reference materials provided in this section. The reference materials may mention use of product that has not been approved or cleared by regulatory agencies in your region or territory. Luminex is providing reference materials for customer information and does not recommend using the product inconsistent with the product’s intended use and labeling.
For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.
*Only xTAG RVP FAST v2 can be used on our MAGPIX system.
Intended Use (EU-IVD/SFDA Approved):
The xTAG® Respiratory Viral Panel Fast v2 (RVP FAST v2) is a qualitative nucleic acid multiplex test intended for the simultaneous detection and identification of multiple respiratory virus nucleic acids in nasopharyngeal swabs, nasal aspirates and bronchioalveolar lavages from individuals suspected of respiratory tract infections.
The detection and identification of specific viral nucleic acids from individuals exhibiting signs and symptoms of respiratory infection aids in the diagnosis of respiratory viral infection when used in conjunction with other clinical and laboratory findings.